We studied 63 patients with myasthenia gravis (MG) requiring treatment with intravenous immunoglobulin, to determine if polymorphisms within the FCγR2A (rs1801274), FCγR2B (rs1050501), FCγR3A (rs396991), and FCγR3B (NA1/NA2) genes are correlated with response to treatment. There was no significant difference in any of the polymorphisms studied between responders and nonresponders. Patients with the FCγR2B-232I/I polymorphism had higher disease severity measured by the quatitative myasthenia gravis score (QMGS). There was no difference in the distribution of the FCγR2B-232 polymorphisms between the patients and 90 healthy controls. The finding of greater disease severity in patients with the FCγR2B-232I/I polymorphism requires confirmation in a larger population of patients with myasthenia gravis. Copyright © 2012 by Lippincott Williams & Wilkins.
CITATION STYLE
Barnett, C., Grinberg, Y., Ghani, M., Rogaeva, E., Katzberg, H., St George-Hyslop, P., & Bril, V. (2012). Fcγ receptor polymorphisms do not predict response to intravenous immunoglobulin in myasthenia gravis. Journal of Clinical Neuromuscular Disease, 14(1), 1–6. https://doi.org/10.1097/CND.0b013e31825c566b
Mendeley helps you to discover research relevant for your work.